Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasm Metastasis 2

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × selitrectinib × Tumor-Agnostic × Clear all
NCT03215511 2024-10-30

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Bayer

Phase 1 Completed
81 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03206931 2021-09-16

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Bayer

No longer available
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡